Immuron Receives AUD $306,154 R&D Tax Concession Refund
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical firm, has successfully claimed a cash refund of AUD $306,154 under the Australian Government’s Research and Development Income Tax Concession program. This refund pertains to eligible research and development expenses from the 2021 Financial Year. The company is committed to developing oral immunotherapeutics for gut-mediated pathogens.
- Received AUD $306,154 refund under the Australian Government's tax incentive for R&D expenses.
- None.
MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD
This release has been authorized by the directors of Immuron Limited.
| COMPANY CONTACT: Dr Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com | US INVESTOR CONTACT Dave Gentry, CEO RedChip Companies Inc. +1-407-491-4498 dave@redchip.com |
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: http://www.immuron.com
FAQ
What is the recent cash refund received by Immuron Limited (IMRN)?
How much did Immuron Limited receive under the R&D tax incentive?
What is the focus of Immuron Limited's business?
